ArticleDiscover oncology2026
A computational framework integrating multi-omics and machine learning for identifying glycolytic gene markers in breast cancer.
Article in Discover oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- NUPR1 in breast cancer: mechanisms and potential applications.Frontiers in physiology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Breast cancer remains a leading cause of cancer-related mortality in women worldwide. Metabolic reprogramming, especially enhanced glycolysis, is a hallmark of breast cancer progression and offers promising targets for therapeutic intervention. However, systematic identification of glycolysis-related gene markers at single-cell resolution remains limited.We integrated single-cell RNA sequencing, spatial transcriptomics, and multiple machine learning algorithms to analyze glycolytic heterogeneity in breast cancer. A novel interquartile range (IQR)-based scoring method was developed to quantify glycolytic activity at the single-cell level. Glycolysis-related genes (GRGs) were systematically screened using five machine learning models (RF, Boruta, Lasso, ABESS, and GBM), and their diagnostic and prognostic values were evaluated.We identified significant glycolytic heterogeneity among breast cancer cell subsets, with malignant cells exhibiting the highest glycolytic activity. Seven hub genes, namely PKM, MIF, SOD1, PGK1, APP, LDHB and NUPR1, were consistently identified and validated. These genes showed strong diagnostic potential with high AUC values in ROC analysis, and their elevated expression was confirmed in breast cancer tissues via immunohistochemistry. Spatial and cell communication analyses further revealed distinct metabolic niches and intercellular signaling networks associated with high-glycolytic cells.This study establishes a robust IQR-based glycolysis assessment strategy that overcomes limitations of previous scoring methods. We identified seven core glycolytic regulatory genes that are closely linked to breast cancer progression and poor prognosis. These findings provide novel insights into metabolic reprogramming in breast cancer and offer potential biomarkers for targeted metabolic therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.